2016
DOI: 10.4172/2155-9570.1000604
|View full text |Cite
|
Sign up to set email alerts
|

Simultaneous Use of Amniotic Membrane and Mitomycin C in Trabeculectomy for Primary Glaucoma: A Pilot Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 8 publications
0
4
0
Order By: Relevance
“…The amniotic membrane has anti-scarring and anti-inflammatory properties in fibrotic eye disease, including glaucoma surgery [10‒12, 37, 38]. The anti-scarring effect of the amniotic membrane is mediated by downregulating TGF-β signalling pathway and myofibroblast differentiation.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The amniotic membrane has anti-scarring and anti-inflammatory properties in fibrotic eye disease, including glaucoma surgery [10‒12, 37, 38]. The anti-scarring effect of the amniotic membrane is mediated by downregulating TGF-β signalling pathway and myofibroblast differentiation.…”
Section: Discussionmentioning
confidence: 99%
“…Previous studies reported that trabeculectomy with amniotic membrane transplantation (AMT) had a lower complication rate and higher success rate than trabeculectomy without AMT [10‒12]. In our previous study, trabeculectomy with AMT was found to be a safe and effective method for intraocular pressure (IOP) reduction in patients with primary open-angle glaucoma (POAG) without the development of avascular cystic blebs or bleb-related infection [12].…”
Section: Introductionmentioning
confidence: 99%
“…AM is known to reduce scarring at the time of the filtering surgery; repair any early or late blebs and act as a protective cover in valve procedures [ 43 ]. When used in conjunction with any glaucoma surgery, AM transplantation is used to protect and cover any exposed sclera to improve both patient outcomes and the rate of complications [ 44 , 45 ]. It should be noted that as AM is a human tissue, it can have variable persistence time dependent on the inflammation present at the ocular surface and the method of application.…”
Section: Glaucomamentioning
confidence: 99%
“…First reported by Fujishima et al [ 47 ] the surgical procedure for AMtransplantation following trabeculectomy is yet to be standardised. Some studies report the placement of the AM below of scleral flap in a ‘inlay-graft’ fashion [ 48 , 49 ], however, other studies state that the tissue is placed over the wound in an ‘onlay-graft’ fashion to over the entire exposed scleral bed [ 32 , 44 , 50 ]. As a whole, data shows the application of AM epithelial-side-down [ 2 ] when placed onto the wound.…”
Section: Glaucomamentioning
confidence: 99%